HemaFus PML-RARA (bcr2) Fusion Gene Quantitative Detection Kit (PCR-Fluorescent Probing)

Background

Acute promyelocytic leukemia (APL) is a distinct subtype of AML characterized by specific chromosomal translocation (t15;17)(q22;q12) in the vast majority of patients. This leads to the formation of the PML-RARA fusion gene (Figure 1), and its protein product causes cell differentiation arrest and apoptosis deficiency, which is the main molecular mechanism of APL development. 

Figure 1

PML/RARA fusion gene is heterogeneous. Since PML gene recombination occurs in different breakpoint cluster regions, three isoforms have been identified (Figure 2): (1) Long isoform (L; Bcr-1), caused by a breakpoint in PML resulting in fusion of RARA (exon 3) with PML (exon 6); (2) Variant isoform (V; Bcr-2), caused by a breakpoint in PML resulting in fusion of RARA (exon 3) with PML (exon 6); (3) Short isoform (S; Bcr-3), caused by a breakpoint in PML resulting in fusion of RARA (exon 3) with PML (exon 3). The PML/RARA fusion gene is highly correlated with AML-M3, and its detection results are helpful for the diagnosis of AML-M3.

Figure 2

Features

Simple operation and less time consumption; reliable results and intuitive interpretation; high sensitivity and sample saving.

Detection Process

The bcr1 subtype of PML-RARA fusion gene is quantitatively detected by fluorescence quantitative PCR.

Ordering Information